Sean A. Mccarthy Sells 14,340 Shares of CytomX Therapeutics, Inc. (CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 14,340 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.60, for a total value of $295,404.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CytomX Therapeutics, Inc. (NASDAQ CTMX) opened at $19.79 on Thursday. CytomX Therapeutics, Inc. has a 52 week low of $10.40 and a 52 week high of $24.67.

A number of research firms recently commented on CTMX. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Bank of America reiterated a “buy” rating and set a $30.00 price objective (up previously from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. Jefferies Group set a $25.00 price objective on CytomX Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 25th. Wedbush began coverage on CytomX Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $26.00 price objective for the company. Finally, ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. CytomX Therapeutics currently has a consensus rating of “Hold” and an average price target of $31.88.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTMX. FMR LLC lifted its position in CytomX Therapeutics by 0.6% during the 2nd quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock worth $85,444,000 after acquiring an additional 34,732 shares in the last quarter. Vanguard Group Inc. lifted its position in CytomX Therapeutics by 12.2% during the 2nd quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock worth $14,323,000 after acquiring an additional 100,607 shares in the last quarter. Redmile Group LLC lifted its position in CytomX Therapeutics by 2.4% during the 2nd quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock worth $10,825,000 after acquiring an additional 16,500 shares in the last quarter. Numeric Investors LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $9,730,000. Finally, State Street Corp lifted its position in CytomX Therapeutics by 58.8% during the 2nd quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock worth $6,914,000 after acquiring an additional 165,342 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Sean A. Mccarthy Sells 14,340 Shares of CytomX Therapeutics, Inc. (CTMX) Stock” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3079549/sean-a-mccarthy-sells-14340-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.